Globotriaosylceramide, Gb3, is an alternative functional receptor for Shiga-like toxin 2e.

Infect Immun

Division of Geographic Medicine and Infectious Diseases, New England Medical Center, Boston, Massachusetts.

Published: March 1995

We reexamined the binding specificity of the Shiga-like toxin variant associated with porcine edema disease, SLT2e, which is reported to be more cytotoxic for Vero cells than for HeLa cells, by using receptor-deficient cells and a liposomal insertion system for purified glycolipids. We found that SLT2e preferentially uses globotetraosylceramide as a receptor but can also cause cytotoxicity by using globotriaosylceramide, the SLT2 receptor. We conclude that the differential cytotoxicity of SLT2e on HeLa and Vero cells is a function of both the receptor preference of the toxin and the specific glycolipid content of the target cells being used.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC173124PMC
http://dx.doi.org/10.1128/iai.63.3.1138-1141.1995DOI Listing

Publication Analysis

Top Keywords

shiga-like toxin
8
vero cells
8
cells
5
globotriaosylceramide gb3
4
gb3 alternative
4
alternative functional
4
receptor
4
functional receptor
4
receptor shiga-like
4
toxin reexamined
4

Similar Publications

Monocytes serve as Shiga toxin carriers during the development of hemolytic uremic syndrome.

Cell Mol Biol Lett

January 2025

State Key Laboratory of Pharmaceutical Biotechnology, Department of Gastroenterology, Drum Tower Hospital, Nanjing University Medical School, Nanjing University, Nanjing, 210093, Jiangsu, China.

Shiga toxin (Stx)-induced hemolytic uremic syndrome (HUS) poses a life-threatening complication for which a definitive treatment remains elusive. To exert its cytotoxic effect on renal cells, Stx must be delivered from the infected intestines to the kidney. However, the mechanism underlying Stx delivery remains unclear.

View Article and Find Full Text PDF

Characterization of Broad Spectrum Bacteriophage vB ESM-pEJ01 and Its Antimicrobial Efficacy Against Shiga Toxin-Producing in Green Juice.

Microorganisms

January 2025

Department of Food Science and Biotechnology, College of Bionano Technology, Gachon University, Seongnam 13120, Republic of Korea.

Shiga toxin-producing (STEC) infections have increased in humans, animals, and the food industry, with ready-to-eat (RTE) food products being particularly susceptible to contamination. The prevalence of multidrug-resistant strains has rendered the current control strategies insufficient to effectively control STEC infections. Herein, we characterized the newly isolated STEC phage vB_ESM-pEJ01, a polyvalent phage capable of infecting and species, and assessed its efficacy in reducing STEC in vitro and food matrices.

View Article and Find Full Text PDF

Hybrid strains of enterotoxigenic/Shiga toxin-producing , United Kingdom, 2014-2023.

J Med Microbiol

January 2025

NIHR Health Protection Research Unit in Gastrointestinal Infections, University of Liverpool, Liverpool, UK.

Diarrhoeagenic (DEC) pathotypes are defined by genes located on mobile genetic elements, and more than one definitive pathogenicity gene may be present in the same strain. In August 2022, UK Health Security Agency (UKHSA) surveillance systems detected an outbreak of hybrid Shiga toxin-producing /enterotoxigenic (STEC-ETEC) serotype O101:H33 harbouring both Shiga toxin () and heat-stable toxin (). These hybrid strains of DEC are a public health concern, as they are often associated with enhanced pathogenicity.

View Article and Find Full Text PDF

In July 2022, a genetically linked and geographically dispersed cluster of 12 cases of Shiga toxin-producing (STEC) O103:H2 was detected by the UK Health Security Agency using whole genome sequencing. Review of food history questionnaires identified cheese (particularly an unpasteurized brie-style cheese) and mixed salad leaves as potential vehicles. A case-control study was conducted to investigate exposure to these products.

View Article and Find Full Text PDF

Shiga Toxin: Emerging Producer Strains, Prophylactic Approaches, and Application in Cancer Therapy.

J Cancer Prev

December 2024

Infectious Disease Research Center, Avicenna Institute of Clinical Sciences, Hamadan, IranAvicenna Health Research Institute, Hamadan University of Medical Sciences, Hamadan, Iran.

Shiga toxin-producing is the most prevalent bacterial strain responsible for Shiga toxin-related infections. While Shiga toxin is inherently toxic, it has potential therapeutic applications as a component of anticancer drugs. Despite its association with infections and harmful effects on human health, Shiga toxin is being explored as a viable element in drug delivery systems targeting cancer cells.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!